Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BioMarin PharmaceuticalBMRN -0.60%76 EV-to-OCF is 18.53 as of Sep. 01, 2026, which is 68% below its 10-year median of 57.65. GuruFocus rates BMRN with a GF Score™ of 76/100 and a GF Value™ of $84.00 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 1,408 Biotechnology companies, BioMarin Pharmaceutical ranks worse than 87.78% on this metric.
The historical rank and industry rank for BioMarin Pharmaceutical's EV-to-OCF or its related term are showing as below:
BMRN'
s EV-to-OCF Range Over the Past 10 Years
Min: -1810.42 Med: 57.65 Max: 2126.23
Current: 18.53
During the past 13 years, the highest EV-to-OCF of BioMarin Pharmaceutical was 2126.23. The lowest was -1810.42. And the median was 57.65.
BMRN's EV-to-OCF is ranked worse than 87.78% of 1408
companies
in the Biotechnology industry
Industry Median: -3.685
vs BMRN: 18.53
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
BioMarin Pharmaceutical's PE Ratio (TTM) for today is calculated as:
BioMarin Pharmaceutical's share price for today is $64.84.
BioMarin Pharmaceutical's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.370.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, BioMarin Pharmaceutical's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioMarin Pharmaceutical EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BioMarin Pharmaceutical's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where BioMarin Pharmaceutical's EV-to-OCF falls into.
BioMarin Pharmaceutical's current Enterprise Value is $15,880 Mil.
BioMarin Pharmaceutical's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $857 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioMarin Pharmaceutical (BMRN) has a EV-to-OCF of 18.53 as of Sep. 01, 2026. This is 68% below median its historical median of 57.65. According to the industry distribution chart, BioMarin Pharmaceutical ranks #1236 out of 1408 companies in the Biotechnology industry, placing it in the top 87.8%.
Is BioMarin Pharmaceutical's EV-to-OCF too high?
BioMarin Pharmaceutical's current EV-to-OCF of 18.53 is 68% below median its 10-year median of 57.65. Based on the distribution chart, BioMarin Pharmaceutical ranks #1236 out of 1408 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, BioMarin Pharmaceutical has a GF Score™ of 76/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does BioMarin Pharmaceutical's EV-to-OCF compare to MDGL and CORT?
According to the Biotechnology industry distribution chart, BioMarin Pharmaceutical ranks #1236 out of 1408 companies for EV-to-OCF. This places BioMarin Pharmaceutical in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. BioMarin Pharmaceutical's current EV-to-OCF is 18.53, which is 68% below median its own 10-year median of 57.65. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioMarin Pharmaceutical stock overvalued right now?
Based on GuruFocus' analysis, BioMarin Pharmaceutical (BMRN) is currently considered Modestly Undervalued. The stock's GF Value™ is $84.00, compared to a current price of $64.84 — trading 22.8% below its estimated fair value. The current EV-to-OCF is 18.53, which is 68% below median its 10-year median of 57.65. BioMarin Pharmaceutical's overall GF Score™ is 76/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For BioMarin Pharmaceutical (BMRN), the current EV-to-OCF is 18.53 as of Sep. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioMarin Pharmaceutical (BMRN) Overvalued in 2026?
Based on GuruFocus' analysis, BioMarin Pharmaceutical stock appears to be undervalued.
The current stock price of $64.84 is trading 22.8% below its estimated GF Value™ of $84.00.
GuruFocus considers BioMarin Pharmaceutical to be Modestly Undervalued.
Key valuation signals for BMRN:
EV-to-OCF: 18.53 (68% below median its 10-year median of 57.65)
GF Value™: $84.00 vs. price of $64.84 (22.8% below fair value)
No single metric tells the full story. See the BMRN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.
76GF Score
Get the complete analysis for BMRN
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BMRN has been successfully added to your 
